Clinical trial
A Clinical Study of the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 for the Treatment of Refractory Lupus Nephritis
NCT06681337 is registered in ClinicalTrials.gov with Bioray Laboratories as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Clinical Study of the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 for the Treatment of Refractory Lupus Nephritis
- Lead sponsor
- Bioray Laboratories
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- November 25, 2024
- Completion date
- December 31, 2025
- Enrollment
- 10 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.